Profound
Profound Medical | Advanced Techniques in Prostate Cancer.
Market cap
$178m
Enterprise value
$136m
Share price
CAD8.10 PRN.TO
Get premium to view all results
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor investor investor investor | €0.0 | round |
| N/A | €0.0 | round | |
| investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
* | N/A | $40.3m | Post IPO Equity |
| Total Funding | 000k | ||
BDC Capital(exited)
Genesys Capital(exited)
CTI Life Sciences(exited)
Amplitude Ventures(exited)
MaRS Investment Accelerator Fund(exited)
CIBC Innovation Banking(exited)
| USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | (6 %) | (3 %) | 8 % | 48 % | 67 % | 110 % | 51 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (413 %) | (381 %) | (361 %) | (336 %) | (229 %) | (102 %) | (64 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (447 %) | (429 %) | (397 %) | (260 %) | (243 %) | (106 %) | (72 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 222 % | 220 % | 200 % | 159 % | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads
Tech stack
Tech stackLearn more about the technologies and tools that this company uses.